INTRODUCTION
Primary biliary cholangitis (PBC) belongs to the liver diseases with an autoimmune background. It is characterized by a chronic cholestatic process which affects small to medium sized bile ducts and is caused by immune-mediated destruction of the epithelium, leading in consequence to cholestasis, and in a proportion of patients to liver impairment and cirrhosis [1] . The presence of the antimitochondrial autoantibodies (AMA) in almost 90% of PBC patients as well as identification of antinuclear antibodies, targeting the sp100 and gp210 antigens in as much as 30% patients [2] [3] [4] , underscore the role of the autoimmune process in the development of PBC. This condition is frequently seen in middle-aged women with other extrahepatic autoimmune disease [5, 6] . Indeed, previously published reports demonstrated that patients with PBC might have a 61% [7] risk of coincidence of more than one disorder connected J Gastrointestin Liver Dis, September 2017 Vol. 26 No 3: 245-252 with autoimmunity. Autoimmune thyroid disease (AITD) is one of the disorders with the highest evidence for association with PBC. Indeed, a recent study [8] demonstrates that 14% of patients with PBC might suffer from AITD. Prevalence of thyroid disorder is confirmed by the presence of positive thyroid antibodies, and is clinically manifested mainly as Hashimoto thyroiditis (HT) or Graves' disease (GD). An extensive number of genetic studies, including analyzes of twin pairs, family studies and genome-wide association studies (GWAS), revealed the evidence of a significant genetic component of hepatic autoimmunity [9, 10] . Given the fact that patients with PBC often develop extrahepatic autoimmune conditions one could hypothesize that genetic background might be responsible for this phenomenon, and that it also might have an impact on the natural history of PBC. Of note, the majority of genetic studies have focused on triggers of PBC, whereas the analysis of genetic variants that might modulate the clinical course of PBC has gained less attention.
In the present study we analyzed 10 variants of genes previously associated with AITD in a large group of patients with PBC. Our aim was to find out whether AITD-triggering polymorphisms might play a role in the development and in the course of PBC and PBC associated with AITD (PBC-AITD).
MATERIAL AND METHODS

Subjects
In this cross-sectional study we prospectively recruited from 2007 to 2016 a total of 230 patients with PBC. All patients were recruited in two Polish university Centres (Pomeranian Medical University, Szczecin and Medical University of Warsaw, Warsaw). The diagnosis of PBC was established according to the European Association for the Study of Liver (EASL) criteria [11] . The presence of acute and chronic liver diseases other than PBC, as well as liver tumors, was excluded in all patients. Fasting venous blood samples were drawn for routine biochemical analyses, including liver function tests, and DNA genotyping. The presence of liver cirrhosis was established either by liver biopsy or imaging screening (e.g. transient elastography [12] ). Serum levels of thyroid peroxidase antibody (TPOAb) in PBC patients were quantified using QUANTA Lite® TPO assay (Inova Diagnostics, San Diego, CA, USA) based on the enzyme-linked immunosorbent assay method (ELISA) [13] . The control group consisted of 421 healthy Polish adults (330 females, 91 males) recruited from subjects requesting paternity testing who gave their consent for anonymous use of their genetic material for scientific research. The protocol of this study conforms to the ethical guidelines of the Declaration of Helsinki as reflected in a priori approval by the institution's Human Research Ethics Committee. All patients and controls gave written informed consent to participate in the study.
SNPs selection and genotyping
Genomic DNA was isolated from peripheral blood mononuclear cells using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) or salting-out method [14] . In all subjects, we analyzed 10 SNPs previously associated with AITD (Table I ). All selected SNPs were genotyped using the predesigned TaqMan SNP genotyping assays provided by Life Technologies, Carlsbad, CA, USA. The genotyping procedure was performed according to the manufacturer's protocol on the QuantStudioTM 12K Flex instrument (Life Technologies).
Statistical analysis P-value less than 0.05 was considered statistically significant. The genotype distributions of the analyzed SNPs in both patients and controls were tested for Hardy-Weinberg Equilibrium (HWE) using the chi-square test. Allele frequencies in patients and in controls as well as in subgroups of patients were compared using the chi-square test or Fisher's exact test, when appropriate and Armitage's trend test was used to confirm association in positive findings. The Shapiro-Wilk test for normality was used to examine the distribution of quantitative variables and 
RESULTS
Characteristics of the study cohort
The clinical and laboratory characteristics of the study group are shown in Table II The PTPN22 polymorphism might increase the risk of developing PBC and PBC-AITD All selected variants were successfully genotyped in cases and controls and their frequencies did not deviate from the frequencies deposited in the ExAc Browser (exac. broadinstitute.org) and were in line with the frequencies 
Associations of the studied variants with liver injury and metabolic traits in the PBC patients
The IL2RA polymorphism was significantly associated with the odds of developing liver cirrhosis in the PBC cohort (OR=1.76, P=0.033, Table V & Suppl. Table C) . As demonstrated in Table II , 40 (17.5%) PBC patients required liver transplantation. Carriers of the MMEL1 polymorphism proved to be at increased risk of requiring liver transplantation (OR=1.70, P=0.023, Table VI) . We also detected a trend of association between liver transplantation and the RNASET2 polymorphism (OR=0.72, P=0.087, Suppl. Table D) . A comprehensive comparison of laboratory features between subgroups of PBC patients with different genotypes for all studied SNPs is shown in Suppl. Table E. Although we did not detect any significant differences in clinical or biochemical characteristics between patients with PBC and PBC-AITD (all P >0.05, Suppl. affected liver tests and metabolic traits. Indeed, as shown in Fig. 1 , both CTLA4 and MMEL1 polymorphisms were associated with serum ALP levels (P=0.005 and P=0.042, respectively), carriers of the PTPN22 variant had higher GGT and cholesterol (P=0.047 and P=0.028, respectively), the CTLA4 variant affected serum triglycerides (P=0.003) whereas the RNASET2 polymorphism was related to albumin concentrations (P=0.018).
genetic studies, including GWAS, performed in patients with PBC have led to the identification of risk loci for this disease [9] . Data concerning genetic modifiers of PBC progression as well as variants that increase the risk of developing autoimmune conditions other than PBC are, in turn, scarce. Therefore in our study we aimed to find risk loci for PBC, but also to detect genetic polymorphisms that affect the progression of the disease and increase the odds for the coincidence of AITD with PBC. Indeed, detection of factors that are associated with a progressive PBC course might help to improve the fate of PBC patients and contribute to a better understanding of the PBC pathogenesis. Our candidate-gene study revealed a few new polymorphisms which are associated with the risk of developing PBC and with the disease progression.
We focused on two issues: genetic triggers of PBC and modifiers of the disease progression. Among tested variants, we found a significant association between the PTPN22 polymorphism and PBC as well as PBC-AITD. Previous studies demonstrated the association of the rs2476601 polymorphism in the PTPN22 gene, which encodes lymphoid-specific protein tyrosine phosphatase non-receptor type 22 (Lyp), with numerous autoimmune conditions, such as diabetes mellitus type 1 (DM1) [19] , rheumatoid arthritis (RA) [20] , systemic lupus erythematosus (SLE) [21] , GD [22, 23] and myasthenia gravis [24] . The relationship between variants of PTPN22 gene and autoimmunity in general is explicable by influence of Lyp on negative control of T-cell activation and T-cell development [25] . An early candidate gene study negated the association between PTPN22 SNPs and predisposition to PBC [26] , also in the GWAS studies no association between this variant and the PBC risk was reported [27] [28] [29] [30] [31] . The latest analysis from Japan however revealed that one of the PTPN22 haplotypes might significantly modulate the risk of developing PBC [32] . Interestingly, our study showed significant association between PTPN22 and concomitance of PBC and AITD. Previous studies connected the PTPN22 polymorphism with an overlap between diabetes mellitus type 1 (DM1) and AITD [33, 34] as well 
DISCUSSION
The pathogenesis of PBC remains unclear. Modifiers of PBC progression have also not been fully elucidated [15] [16] [17] . Nevertheless, as much as 26% of patients with PBC are expected to develop liver cirrhosis within 5 years from diagnosis despite the ursodeoxycholic acid (UDCA) treatment [18] . Numerous as with a susceptibility to DM1, rheumatoid arthritis (RA), systemic lupus erythomatosus (SLE), and HT in members of the families with history of multiplex autoimmune diseases [35] . Therefore, the PTPN22 gene polymorphism seems to play an important role in the shared susceptibility to autoimmune diseases.
Further analyses revealed that the rs41295061 polymorphism of the IL2RA gene, which encodes the alpha subunit of the interleukin 2 receptor, also known as CD25, is associated with increased risk of developing liver cirrhosis. The latest GWAS [36, 37] attributed the risk of hepatic autoimmunity to several new loci and among this group was the IL2RA gene. Of note, previously a homozygous mutation of IL2RA was described in a pediatric patient causing PBC-like syndrome with positive serological signs [38] . It has been proven that immunological pathways involving T-cell activation might play an important role in the pathogenesis of PBC [39, 40] Fig. 1 . Associations between the studied SNPs and biochemical parameters in PBC patients. Kruskal-Wallis ANOVA test was used to compare quantitative traits with non-normal distribution in PBC patients stratified by genotype for each SNP. Significant associations (all P<0.05) were observed between the CTLA4 (rs3087243) and MMEL1 (rs2843403) polymorphisms and alkaline phosphatase (ALP) levels (A, B), the PTPN22 (rs2476601) polymorphism and gamma-glutamyl transpeptidase (GGT) and cholesterol levels (C, D), the CTLA4 (rs3087243) polymorphism and serum triglycerides levels (E), and the RNASET2 (rs9355610) polymorphism and albumin concentrations (F), as presented below. In each plot, the black square within the box indicates the median value, boundaries of each box indicate the 25th-75th percentile range, and whiskers indicate the highest and lowest values in each subgroup of PBC patients. [46] and primary sclerosing cholangitis (PSC) [36] suggest that this locus modulates the susceptibility to develop autoimmune conditions. However, the link between the need of liver transplantation among carriers of this variant is a novel finding which requires confirmation in larger cohorts of patients with PBC. To our knowledge, there is no detailed description of MMEL1 function that might explain the observed association. Given the involvement of the MMEL1 in the pathogenesis of several autoimmune conditions, one could hypothesize that carriers of the MMEL1 variant might have an increased tendency to autoimmune response leading to a rapid progression of the liver disease. Moreover, the analyzed MMEL1 polymorphism is located in a region of strong linkage disequilibrium on chromosome 1, near the tumour necrosis factor receptor superfamily 14 (TNFRSF14) gene, involved in signal transduction pathways that activate inflammatory response [45] . We reckon that further investigations are needed to elucidate the role of the MMEL1 polymorphism in the development of PBC and its overlap with other autoimmune conditions.
Of note, in our cohort of patients AITD per se did not seem to significantly influence the natural history of PBC. These results are in line with findings from other European groups, which demonstrated that presence of extrahepatic autoimmune conditions does not significantly affect the survival of patients with PBC [7, 8] . Furthermore, Muratori et al. [47] showed no differences between subgroups of PBC patients with and without concomitant autoimmune disorder in terms of age at diagnosis, serum level of antibodies and long-term complications of liver disease. On the other hand, Rigamonti et al. [48] reported a slower progression of liver disease in PBC patients with coexisting systemic sclerosis, whereas Wang et al. [49] observed certain differences in the laboratory features between Chinese PBC patients with and without overlapping connective tissue disease. These interesting results should be verified in future studies concerning presence of extrahepatic autoimmune conditions and progression of chronic cholestatic disorders.
There are several limitations of this study. First, whereas a number of studies suggest that the genetic background of many autoimmune conditions may be different in various populations, all PBC patients analyzed in the current study were Polish Caucasians: therefore, our results require confirmation in non-Caucasian populations and in cohorts from other European countries. Moreover, although the presence of TPO antibodies usually precedes the development of an overt thyroid disease, we do not have precise data on the thyroid status and thyroid hormones levels in the PBC patients included in our study. Finally, functional studies are necessary to elucidate the underlying mechanisms behind the reported associations
CONCLUSION
Our study suggests the presence of several polymorphisms that are associated with shared susceptibility to AITD and PBC. Some of them might contribute to the clinical course of PBC and determine the levels of biochemical parameters. These results underscore the existence of a shared genetic predisposition between AITD and PBC and might help to design new tailored strategies aiming at patients carrying genetic variants associated with progressive PBC. Further studies are warranted to investigate how shared genetic predisposition between cholestatic liver disease and extrahepatic autoimmune disorders might affect the progression of liver injury. 
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